In brief
A funded proposal to build real-world evidence on how to safely reduce antipsychotic use for dementia-related symptoms in nursing-home residents; it describes aims and methods, not results.
What this article is about
Quick Answer
A funded proposal to build real-world evidence on how to safely reduce antipsychotic use for dementia-related symptoms in nursing-home residents; it describes aims and methods, not results.
Student takeaways
Key Takeaways
- This is a funded research proposal; it presents background, aims, and planned methods, not outcome results about deprescribing.
- As context, the abstract states about 40-45% of people with ADRD live in skilled nursing facilities and BPSD affects roughly 80% of them, with antipsychotics the most common pharmacological treatment.
- The rationale notes antipsychotics carry numerous adverse effects and guidelines recommend short, acute-only use, yet they are often continued six months or longer.
- The team plans a large observational study of more than 370,000 SNF residents with ADRD (2013-2026), combining Medicare claims, EHR, MDS, and CASPER data with advanced confounding-control methods.
- Three aims are proposed: describe prescribing and discontinuation patterns and barriers; compare outcomes of discontinuation strategies (abrupt versus gradual tapering) versus continuation; and test whether effects differ by patient phenotype.
Student summary
Why This Research Matters
This document is a funded research proposal from the National Institute on Aging. It describes a planned study, its rationale, and its methods; it does not report results. That distinction matters for a health-related topic like this one: the investigators outline what they intend to learn, not what they have found. Any numbers below describe background context or study design, not outcomes of this project. The clinical problem is the use of antipsychotic medications (APMs) to manage behavioral and psychological symptoms of dementia (BPSD) in skilled nursing facilities (SNFs). The proposal notes that about 40 to 45 percent of people living with Alzheimer's disease and related dementias (ADRD) live in an SNF, and that BPSD, symptoms such as agitation, aggression, or distress, occur in roughly 80 percent of these residents. Antipsychotics are described as the most commonly used medication for these symptoms. A central tension drives the study. Antipsychotics are associated with numerous adverse effects, and clinical guidelines recommend using them only for acute episodes and stopping them as soon as possible. (As general background, regulators have long warned that antipsychotics increase the risk of death when used in older adults with dementia, which is why cautious, time-limited use is emphasised.) Yet in practice, the proposal notes, these drugs are often continued for six months or longer. The evidence on how best to stop them is described as weak: earlier small randomized controlled trials comparing withdrawing versus continuing antipsychotics produced conflicting results and appeared to show little benefit from stopping, but those trials were underpowered and left out the frail, complex older adults who are most common in real nursing-home care. To address this gap, the investigators propose a large observational study rather than a new trial. They plan to combine Medicare claims data with electronic health records, the Minimum Data Set (MDS), and Certification and Survey Provider Enhanced Reporting (CASPER) data, covering more than 370,000 older adults with ADRD living in SNFs between 2013 and 2026. Because people are not randomly assigned to stop or continue medication in real life, the plan relies on advanced statistical methods, including a clone-censor-weight approach, machine-learning-aided adjustment, external adjustment, and instrumental variable analysis, all intended to reduce confounding, especially confounding by how severe a person's symptoms or disease are. The proposal sets out three aims: first, to describe how antipsychotics are prescribed and stopped and what barriers get in the way; second, to compare health outcomes for different discontinuation strategies, such as stopping abruptly versus tapering the dose gradually at different rates, against continuing the medication; and third, to see whether the best approach differs for different types of patients, so that deprescribing decisions can be tailored. For nursing students, this proposal highlights several enduring lessons. Deprescribing, the planned, supervised reduction or stopping of a medication, is an active clinical skill, not simply the absence of prescribing. Nurses in long-term care are often the first to notice both BPSD and medication side effects, and their observations feed decisions about whether a drug is still needed. The study also illustrates why non-drug approaches to BPSD, such as identifying unmet needs, pain, or environmental triggers, matter so much: they can reduce reliance on medications that carry real risks. Important cautions apply. This is a research plan, so it offers no conclusions about which deprescribing strategy is safest or most effective; those answers await the completed study. Nothing here should be read as instructions to start or stop any medication. Decisions to reduce or discontinue antipsychotics in a person with dementia must be individualised and made by the care team, with monitoring for the return of distressing symptoms. It is also worth noting that although this record is tagged with the keyword 'schizophrenia,' the study is actually about antipsychotic use for dementia-related symptoms, not the treatment of schizophrenia; antipsychotics are simply used across several conditions. In short, this is a rigorous plan to build stronger, real-world evidence on how to safely reduce antipsychotic use in nursing-home residents with dementia. Its value lies in the questions it asks and the methods it proposes, not in results, which do not yet exist.
Source abstract
Study Overview
Project Summary About 40-45% of people living with Alzheimer’s disease and related dementias (ADRD) reside in a skilled nursing facility (SNF). Behavioral and psychological symptoms of dementia (BPSD) occur in ~80% of older adults with ADRD living in an SNF. Antipsychotic medications (APMs) are the most commonly used pharmacological treatment for BPSD. Because APMs are associated with numerous adverse events, clinical guidelines recommend that their use should be limited to managing acute episodes and discontinued as soon as possible. However, studies have shown that APMs are often used in individuals with ADRD for sustained periods (≥6 months). Small randomized controlled trials (RCTs) comparing withdrawing vs. continuing APMs used for BPSD have yielded conflicting and confusing results that suggested deprescribing APMs had little or no benefits for adverse events. These RCTs were clearly underpowered, and they severely underrepresented frail and complex older adults with ADRD in routine care. There was also a lack of non-randomized studies addressing this critical knowledge gap because deprescribing APMs for behavior disturbance is highly informed by symptom severity, and confounding by disease severity can be very difficult to control unless detailed clinical information is available for research. Our objective is to assess the health effects of different APM deprescribing strategies for managing BPSD in an SNF. To provide solid evidence guiding the deprescribing process, we will assess the effects of discontinuing APMs with vs. without gradual dose reduction and different rates of dose tapering. We will integrate Medicare claims data with electronic health records (EHR), Minimum Data Set (MDS), and Certification and Survey Provider Enhanced Reporting (CASPER), covering >370,000 older adults with ADRD living in an SNF from 2013 to 2026. We will employ the clone-censor-weight approach, high-dimensional machine-learning-aided proxy adjustment methods, external adjustment, and instrumental variable analysis to minimize measured and unmeasured confounding. We will address three specific aims: 1) To evaluate the prescribing and discontinuation patterns and determine the barriers to APMs deprescribing among older adults with BPSD in an SNF. 2) To determine comparative health outcomes of different discontinuation strategies vs. continuation of APMs used for BPSD in older adults who reside in an SNF. 3) To determine the treatment effect heterogeneity by key clinical phenotypes when comparing continuation vs. different discontinuation strategies of APMs used for BPSD in older adults who reside in an SNF so that such deprescribing decisions can be tailored according to patient characteristics. The impact of this proposal is high because it will generate direct evidence to inform optimal management of psychotropic medications in older adults with ADRD living in an SNF. It will also yield a scalable analytical framework specializing in comparative safety and effectiveness analyses of deprescribing psychotropic treatments for behavioral and psychological symptoms of dementia.
Evidence appraisal
Main Findings
- This is a funded research proposal; it presents background, aims, and planned methods, not outcome results about deprescribing.
- As context, the abstract states about 40-45% of people with ADRD live in skilled nursing facilities and BPSD affects roughly 80% of them, with antipsychotics the most common pharmacological treatment.
- The rationale notes antipsychotics carry numerous adverse effects and guidelines recommend short, acute-only use, yet they are often continued six months or longer.
- The team plans a large observational study of more than 370,000 SNF residents with ADRD (2013-2026), combining Medicare claims, EHR, MDS, and CASPER data with advanced confounding-control methods.
- Three aims are proposed: describe prescribing and discontinuation patterns and barriers; compare outcomes of discontinuation strategies (abrupt versus gradual tapering) versus continuation; and test whether effects differ by patient phenotype.
Practice transfer
Clinical Relevance
- Nurses in long-term care are often first to observe both BPSD and medication side effects, and their documentation informs whether an antipsychotic is still needed.
- Deprescribing is an active, monitored process; any dose reduction should be individualised, supervised, and watched for the return of distressing symptoms.
- Non-pharmacological strategies, addressing pain, unmet needs, and environmental triggers, are first-line for many BPSD and can reduce reliance on risky medications.
- Because the study reports no results, nurses should not change practice based on this source; it defines questions, not answers.
- General background warnings about increased mortality with antipsychotics in dementia reinforce cautious, time-limited, closely monitored use, never casual continuation.
Faculty notes
Educational Relevance
This NIA-funded proposal is an excellent teaching vehicle for pharmacovigilance, deprescribing, and causal inference from real-world data. Emphasise first that it is a protocol: it presents aims, rationale, and methods, not outcomes, so students must not infer that any deprescribing strategy is superior. Use it to teach the appropriate use and risks of antipsychotics for behavioral and psychological symptoms of dementia (BPSD), including the guideline preference for short, acute-only courses and the regulatory warnings on mortality in dementia. The proposal is a natural entry point to confounding by indication and disease severity, and to why underpowered trials that exclude frail patients can mislead. Introduce advanced methods, clone-censor-weight, high-dimensional proxy adjustment, and instrumental variables, at a conceptual level, focusing on why observational designs need them. Clinically, connect to the nurse's role in monitoring BPSD, documenting response, championing non-pharmacological interventions, and participating in gradual dose reduction. A useful critique prompt: what are the limits of claims-based outcomes, and how might residual confounding persist? Note the metadata mismatch, the 'schizophrenia' tag versus a dementia-focused study, as a lesson in reading past labels to the actual population and question.
Critical appraisal
Limitations
- As a protocol, the source provides no outcomes; which deprescribing strategy is safest or most effective remains unknown from this document.
- The planned design is observational and relies on statistical adjustment; residual confounding, especially by disease severity, may persist despite advanced methods.
- Claims and administrative data may not capture symptom severity, quality of life, or family and patient preferences well.
Classroom use
Discussion Questions
- What is deprescribing, and why is it considered an active clinical skill rather than simply not prescribing?
- Why do guidelines recommend limiting antipsychotics for BPSD to short, acute episodes?
- What is 'confounding by indication or disease severity,' and why does it complicate studying deprescribing?
- Why might small randomized trials that exclude frail, complex patients give misleading results?
- What are the strengths and weaknesses of using Medicare claims and administrative data to study medication outcomes?
- How can nurses contribute to safe deprescribing of antipsychotics in nursing-home residents?
- What non-pharmacological approaches can help manage behavioral and psychological symptoms of dementia?
- Why is it unsafe to stop antipsychotics abruptly without a care-team plan and monitoring?
- How could the 'right' deprescribing strategy differ from one patient to another?
- Why is it important to read past a study's keyword tags to the actual population and research question?
Search-ready answers
Frequently asked questions
Does this study tell us the safest way to stop antipsychotics?
No. It is a research proposal; it defines the questions and methods but reports no results.
What are antipsychotics used for in this context?
To manage behavioral and psychological symptoms of dementia, such as agitation or aggression.
Are antipsychotics dangerous in older adults with dementia?
They carry notable risks and regulatory mortality warnings, so guidelines urge short, monitored, acute-only use.
Should families stop these medications on their own?
No. Any reduction must be planned and monitored by the care team to watch for returning symptoms.
What is deprescribing?
The intentional, supervised process of reducing or stopping a medication that may no longer be needed or may be harmful.
Why not just run another randomized trial?
Prior small trials were underpowered and excluded frail patients; this large observational study aims to reflect real-world care.
What is confounding by disease severity?
When sicker patients differ systematically from others, making it hard to tell if outcomes come from the drug or the underlying illness.
What non-drug options exist for BPSD?
Identifying and treating pain, unmet needs, and environmental triggers, plus tailored behavioural and environmental approaches.
Is this study about schizophrenia?
No; despite its keyword tag, it studies antipsychotic use for dementia-related symptoms.
What is the nurse's role?
Observing and documenting symptoms and side effects, advocating for non-drug approaches, and monitoring closely during any dose changes.